As per the data presented at the AACR 2024 conference, of the 21 patients who received AZD1390 in conjunction with radiation therapy at manageable doses, the median overall survival (OS) stood at 12.7 months.
In arm A, comprising 75 patients with recurrent glioblastoma, the combination therapy of AZD1390 and IMRT was well-tolerated, primarily resulting in low-grade and reversible adverse effects. Fatigue, nausea, and headache were among the common treatment-emergent adverse effects (TEAEs). In addition, the dose-limiting toxicities included skeletal muscle issues, with a maximum tolerated dose of 400 mg once daily identified for AZD1390. Overall, 9.3% of patients s...
